

Supplementary Table 1 Participant characteristics and impact on subsequent reported bacterial skin infections

Factor (at randomization to stop versus continue cotrimoxazole unless stated)		Overall N (col %) or median (IQR)	Never reported bacterial skin infection N (row %) or median (IQR)	Ever reported bacterial skin infection N (row %) or median (IQR)	P (unadjusted)
Randomized to	Stop cotrimoxazole Continue cotrimoxazole	376 (50%) 382 (50%)	257 (67%) 320 (85%)	125 (33%) 56 (15%)	<0.001
Years on ART		2.1 (1.8,2.3)	2.1 (1.8,2.3)	2.1 (1.8,2.3)	0.12
Age (years)	(per year older)	7 (4,11)	8 (4,11)	7 (4,9)	0.08
Sex	Male Female	360 (47%) 398 (53%)	276 (77%) 301 (76%)	84 (23%) 97 (24%)	0.80
CD4%	(per 1% higher)	33 (26,39)	32 (26,38)	33 (27,39)	0.60
CD4 (cells/mm3)		894 (576,1375)	876 (570,1369)	917 (590,1380)	0.66
CD4 <500		145 (19%)	105 (72%)	40 (28%)	0.28
Weight-for-age		-1.3 (-1.9,-0.6)	-1.2 (-1.9,-0.6)	-1.3 (-2.0,-0.7)	0.21
Height-for-age		-1.8 (-2.5,-1.1)	-1.7 (-2.5,-1.1)	-2.0 (-2.7,-1.1)	0.09
WHO stage (worst)	1 or 2 3 4	203 (27%) 448 (59%) 107 (14%)	169 (83%) 328 (73%) 80 (75%)	34 (17%) 120 (27%) 27 (25%)	0.02
ART	3TC ABC EFV 3TC ABC NVP ZDV 3TC ABC LPV/r second-line	204 (27%) 298 (39%) 252 (33%) 4 (0.5%)	169 (83%) 212 (71%) 192 (76%) 4 (100%)	35 (17%) 86 (29%) 60 (24%) 0 (0%)	0.02
Pre-ART CD4%		13 (8,18)	13 (8,18)	13 (8,18)	0.78
Pre-ART CD4		390 (198,740)	394 (189,740)	380 (218,736)	0.77
Pre-ART weight-for-age		-2.2 (-3.2,-1.3)	-2.1 (-3.2,-1.2)	-2.5 (-3.5,-1.3)	0.10
Pre-ART height-for-age		-2.4 (-3.3,-1.4)	-2.3 (-3.2,-1.4)	-2.7 (-3.4,-1.5)	0.09
Centre	Entebbe, Uganda (rural) Kampala, Uganda (urban) Mulago, Uganda (urban) Harare, Zimbabwe (urban)	153 (20%) 173 (23%) 189 (25%) 243 (32%)	106 (69%) 139 (80%) 140 (74%) 192 (79%)	47 (31%) 34 (20%) 49 (26%) 51 (21%)	0.07
ART monitoring	Laboratory (CD4s) Clinical (no CD4s)	374 (49%) 384 (51%)	284 (75%) 293 (76%)	90 (24%) 91 (24%)	0.93
House walls	Brick (versus other)	690 (91%)	531 (77%)	159 (23%)	0.10
House roof	Corrugate (versus other)	684 (90%)	521 (76%)	163 (24%)	0.89
House rooms		3 (2,4)	3 (2,4)	3 (2,4)	0.80
House sleeping rooms		2 (1,2)	2 (1,2)	2 (1,3)	0.97
Housing	Poor Adequate Good	92 (12%) 222 (30%) 431 (58%)	68 (74%) 169 (76%) 328 (76%)	24 (26%) 53 (24%) 103 (24%)	0.90
Electricity	Yes	451 (60%)	357 (79%)	94 (21%)	0.02
Water	Domestic tap Standpipe Well	443 (59%) 124 (16%) 189 (25%)	350 (79%) 97 (78%) 128 (68%)	93 (21%) 27 (22%) 61 (32%)	0.009
Household asset score*		-0.7 (-0.9,+0.8)	-0.7 (-0.9,+1.1)	-0.9 (-1.3,-0.0)	0.003
Monthly household income (\$)**		125 (75,230)	135 (75,250)	115 (75,225)	0.10
Percentage spent on	Food	21 (11,40)	20 (10,40)	25 (13,50)	0.04

Factor (at randomization to stop versus continue cotrimoxazole unless stated)	Overall N (col %) or median (IQR)	Never reported bacterial skin infection N (row %) or median (IQR)	Ever reported bacterial skin infection N (row %) or median (IQR)	P (unadjusted)
Medicines	7 (2,13)	7 (2,12)	7 (2,13)	0.92
School	18 (0,39)	19 (2,40)	12 (0,30)	0.04
Transport	4 (2,10)	4 (2,10)	5 (2,13)	0.05
Energy	7 (3,10)	7 (3,10)	7 (3,10)	0.92
Rent	4 (0,20)	5 (0,20)	0 (0,20)	0.31
Primary carer Mother (vs other)	434 (57%)	322 (74%)	112 (26%)	0.17
Number of other children in house	2 (1,3)	2 (1,3)	2 (1,3)	0.14
Number of adults in house	3 (2,5)	3 (2,5)	3 (3,5)	0.71

* Calculated as the first principal component of 9 household items (refrigerator, radio, television, video player, landline telephone, mobile phone, motorbike, bicycle, car)

** Recorded in \$ (US dollars) in Zimbabwe: converted from Ugandan shillings to US dollars at a nominal rate of 2000 (average over the period of study)

Note: Percentages given of complete cases: 13 missing housing quality, 3 missing electricity; 30 missing income. P-values from ranksum tests (continuous factors) or exact tests (categorical factors).

Supplementary Table 2 Prevalence of skin conditions and other symptoms at randomisation to stop vs continue cotrimoxazole

	Continue cotrimoxazole N (%)	Stop cotrimoxazole N (%)	p
Bacterial skin infection	6 (1.6%)	4 (1.0%)	0.54
Fungal skin infection	22 (5.9%)	16 (4.2%)	0.32
Viral skin infection	3 (0.8%)	3 (0.8%)	1.00
PPE	6 (1.6%)	3 (0.8%)	0.34
Dermatitis	9 (2.4%)	7 (1.8%)	0.62
Other skin infection	1 (0.3%)	2 (0.5%)	1.00
Fever	26 (6.9%)	28 (7.3%)	0.89
Weight loss	4 (1.1%)	4 (1.0%)	1.00
Weakness/tiredness	1 (0.3%)	1 (0.3%)	1.00
Pallor	0 (0.0%)	0 (0.0%)	-
jaundice/yellow eyes	1 (0.3%)	0 (0.0%)	0.50
Rash	21 (5.6%)	14 (3.7)	0.23
New bruises/masses/bumps	4 (1.1%)	8 (2.1%)	0.38
Muscle aching/pain	0 (0.0%)	0 (0.0%)	-
Abdominal aching/pain	6 (1.6%)	9 (2.4%)	0.60
Poor appetite	6 (1.6%)	8 (2.1%)	0.79
Difficulty feeding	0 (0.0%)	0 (0.0%)	-
Sore mouth /throat/ulcers/thrush	3 (0.8%)	3 (0.8%)	1.00
Vomiting/nausea	5 (1.3%)	5 (1.3%)	1.00
Chronic, bloody or moderate-severe Diarrhoea	3 (0.8%)	3 (0.8%)	1.00
Dehydration	0 (0.0%)	0 (0.0%)	-
Cough	151 (40.2%)	140 (36.6%)	0.33
Difficult/fast breathing	0 (0.5%)	0 (0.0%)	0.25
Ear discharge/pain	9 (2.4%)	10 (2.6%)	1.00
Difficulty walking	0 (0.0%)	0 (0.0%)	-
Delayed developmental milestones	0 (0.0%)	0 (0.0%)	-
New visual problems	6 (1.6%)	11 (2.9%)	0.33
Poor sleep/bad dreams	0 (0.0%)	0 (0.0%)	-
Funny feeling/numbness/pain in Hands or feet	0 (0.0%)	0 (0.0%)	-
Depression/withdrawn	0 (0.0%)	0 (0.0%)	-
Severe headache	3 (0.8%)	9 (2.4%)	0.14

Note: p-values from exact test.